These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31288807)

  • 1. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N; Nolte I; Wall L; Sehn M; Raue J; Pilgram A; Rumstedt K; Bach JP
    BMC Vet Res; 2019 Jul; 15(1):237. PubMed ID: 31288807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
    Klein S; Nolte I; Rumstedt K; Sehn M; Raue JF; Weiner F; Treese JS; Beyerbach M; Bach JP
    BMC Vet Res; 2021 Sep; 17(1):310. PubMed ID: 34563187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    Iwanuk N; Wall L; Nolte I; Raue J; Rumstedt K; Pilgram A; Sehn M; Rohn K; Bach JP
    PLoS One; 2019; 14(10):e0223164. PubMed ID: 31581204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom.
    Mattin MJ; Brodbelt DC; Church DB; Boswood A
    J Vet Intern Med; 2019 Mar; 33(2):445-454. PubMed ID: 30565334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease.
    Hezzell MJ; Boswood A; Chang YM; Moonarmart W; Souttar K; Elliott J
    J Vet Intern Med; 2012; 26(2):302-11. PubMed ID: 22369312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of submaximal treadmill exercise testing and assessments of cardiac biomarkers NT-proBNP and cTnI in dogs with presymptomatic mitral regurgitation.
    Wall L; Mohr A; Ripoli FL; Schulze N; Penter CD; Hungerbuehler S; Bach JP; Lucas K; Nolte I
    PLoS One; 2018; 13(6):e0199023. PubMed ID: 29902265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom.
    Mattin MJ; Boswood A; Church DB; Brodbelt DC
    J Vet Intern Med; 2019 Mar; 33(2):432-444. PubMed ID: 30357909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
    J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration.
    Ruaux C; Scollan K; Suchodolski JS; Steiner JM; Sisson DD
    Vet Clin Pathol; 2015 Sep; 44(3):420-30. PubMed ID: 26108974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M; Ferasin L; Lamb K; Bussadori C; Chiavegato D; D'Agnolo G; Migliorini F; Poggi M; Santilli RA; Guillot E; Garelli-Paar C; Toschi Corneliani R; Farina F; Zani A; Dirven M; Smets P; Guglielmini C; Oliveira P; Di Marcello M; Porciello F; Crosara S; Ciaramella P; Piantedosi D; Smith S; Vannini S; Dall'Aglio E; Savarino P; Quintavalla C; Patteson M; Silva J; Locatelli C; Baron Toaldo M
    J Vet Cardiol; 2020 Feb; 27():34-53. PubMed ID: 32032923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease.
    Klein S; Nolte I; Granados-Soler JL; Lietz P; Sehn M; Raue JF; Rohn K; Packeiser EM; Bach JP
    BMC Vet Res; 2022 Jul; 18(1):256. PubMed ID: 35780161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Troponin I and Amino-Terminal Pro B-Type Natriuretic Peptide in Dogs With Stable Chronic Kidney Disease.
    Pelander L; Häggström J; Ley CJ; Ljungvall I
    J Vet Intern Med; 2017 May; 31(3):805-813. PubMed ID: 28370332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
    Serres F; Pouchelon JL; Poujol L; Lefebvre HP; Trumel C; Daste T; Sampedrano CC; Gouni V; Tissier R; Hawa G; Chetboul V
    J Vet Cardiol; 2009 Dec; 11(2):103-21. PubMed ID: 19850546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NT-ProBNP and cardiac troponin I in virulent canine babesiosis.
    Lobetti R; Kirberger R; Keller N; Kettner F; Dvir E
    Vet Parasitol; 2012 Dec; 190(3-4):333-9. PubMed ID: 22884910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.